LON:GNSGenus Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 3,320 -32.00 (-0.95 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range 3,316.15Now: GBX 3,320▼ 3,38850-Day Range 3,160MA: GBX 3,404.68▼ 3,67252-Week Range 2,460Now: GBX 3,320▼ 3,760Volume79,192 shsAverage Volume78,154 shsMarket Capitalization£2.16 billionP/E Ratio57.64Dividend Yield0.83%BetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendInsider TradesHeadlines Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingGenus has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 3,334.40, Genus has a potential upside of 0.4% from its current price of GBX 3,320.Amount of Analyst CoverageGenus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesGenus has received 340 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenus has received 285 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenus has received 54.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote “Outperform” if you believe GNS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 2.5 Dividend Strength Dividend LeadershipGenus is a leading dividend payer. It pays a dividend yield of 0.83%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGenus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genus is 48.61 %. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genus insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £270,750 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genus are expected to decrease by -100.00% in the coming year, from GBX 7,980 to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is 57.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is 57.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.63.Price to Book Value per Share RatioGenus has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:GNS Previous Symbol CUSIPN/A CIKN/A Webwww.genusplc.com Phone+44-1256-347100Debt Debt-to-Equity Ratio27.93 Current Ratio1.81 Quick Ratio1.12Price-To-Earnings Trailing P/E Ratio57.64 Forward P/E Ratio0.42 P/E GrowthN/A Sales & Book Value Annual Sales£520.40 million Price / Sales4.15 Cash FlowGBX 46.88 per share Price / Cash Flow70.81 Book ValueGBX 764.60 per share Price / Book4.34Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees2,900 Outstanding Shares65,090,300Market Cap£2.16 billion Next Earnings DateN/A OptionableNot Optionable LSE:GNS Rates by TradingView Receive GNS News and Ratings via Email Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter. Genus (LON:GNS) Frequently Asked Questions How has Genus' stock been impacted by COVID-19 (Coronavirus)? Genus' stock was trading at GBX 3,472 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNS shares have decreased by 4.4% and is now trading at GBX 3,320. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Genus? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genus. How often does Genus pay dividends? What is the dividend yield for Genus? Genus declared a dividend on Thursday, February 27th. Shareholders of record on Thursday, March 5th will be paid a dividend of GBX 9.40 per share on Thursday, April 2nd. This represents a dividend yield of 0.3%. The ex-dividend date is Thursday, March 5th. The official announcement can be seen at this link. View Genus' dividend history. What price target have analysts set for GNS? 5 Wall Street analysts have issued twelve-month price targets for Genus' shares. Their forecasts range from GBX 3,200 to GBX 3,550. On average, they anticipate Genus' stock price to reach GBX 3,334.40 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View analysts' price targets for Genus. Has Genus been receiving favorable news coverage? News articles about GNS stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Genus earned a news impact score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutGenus. Who are some of Genus' key competitors? Some companies that are related to Genus include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), Vir Biotechnology (VIR), MorphoSys (MOR), BTG (BTG), Abcam (ABC), Cronos Group (CRON), Kodiak Sciences (KOD), Viela Bio (VIE), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV) and BELLUS Health (BLU). View all competitors. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco Plc Ads (BATS), Cronos Group (CRON), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE) and Experian (EXPN). Who are Genus' key executives? Genus' management team includes the following people: Mr. Karim Bitar, CEO & Exec. Director (Age 54)Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 59)Dr. Jonathan Lightner, Chief of R&D and Scientific OfficerMr. Dan Hartley, Group Gen. Counsel & Company Sec.Ms. Angelle R. Rosata, Group HR Director What is Genus' stock symbol? Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS." How do I buy shares of Genus? Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Genus' stock price today? One share of GNS stock can currently be purchased for approximately GBX 3,320. How big of a company is Genus? Genus has a market capitalization of £2.16 billion and generates £520.40 million in revenue each year. Genus employs 2,900 workers across the globe. What is Genus' official website? The official website for Genus is www.genusplc.com. How can I contact Genus? Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100. This page was last updated on 6/5/2020 by MarketBeat.com Staff
